Potential of transposon-mediated cellular reprogramming towards cell-based therapies

doi:10.4252/wjsc.v12.i7.527

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 7

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9596)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-1) series.

Item

Count

PDF

531

WORD

235

HTML

5055

Figures (1-3)

462

Tables (1-1)

292

Sum=6575

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

473

Download

818

Sum=1291

Publishing Process of This Article

Item

Count

Browse

776

Download

954

Sum=1730

Jul 26, 2020 (publication date) through Nov 28, 2024

Times Cited of This Article

Times Cited (14)

Journal Information of This Article

Publication Name

World Journal of Stem Cells

ISSN

1948-0210

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Stem Cells. Jul 26, 2020; 12(7): 527-544
Published online Jul 26, 2020. doi: 10.4252/wjsc.v12.i7.527

Full Size Figure Download Figure

Figure 3 Timeline of transposon-mediated cellular reprogramming of porcine somatic cells to induced pluripotent stem cells (A), change in the morphology of somatic cells in the culture after transposition (B, unpublished own data), timeline of virus mediated cellular reprogramming of somatic cells to induced pluripotent stem cells (C). iPS: Induced pluripotent stem; MEF: Mouse embryonic fibroblast.

Citation: Kumar D, Anand T, Talluri TR, Kues WA. Potential of transposon-mediated cellular reprogramming towards cell-based therapies. World J Stem Cells 2020; 12(7): 527-544
URL: https://www.wjgnet.com/1948-0210/full/v12/i7/527.htm
DOI: https://dx.doi.org/10.4252/wjsc.v12.i7.527